Cancer Biotherapy And Radiopharmaceuticals

Cancer Biotherapy And Radiopharmaceuticals

癌症生物治疗和放射性药物

  • 4区 中科院分区
  • Q2 JCR分区

期刊简介

《Cancer Biotherapy And Radiopharmaceuticals》是由Mary Ann Liebert Inc.出版社于1996年创办的英文国际期刊(ISSN: 1084-9785,E-ISSN: 1557-8852),该期刊长期致力于医学:研究与实验领域的创新研究,主要研究方向为医学-核医学。作为SCIE收录期刊(JCR分区 Q2,中科院 4区),本刊采用OA未开放获取模式(OA占比0.0378...%),以发表医学:研究与实验领域等方向的原创性研究为核心(研究类文章占比92.59%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在27篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Cancer Biotherapy And Radiopharmaceuticals审稿周期约为 约3月 。该刊近年未被列入国际预警名单,年发文量约27篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 27 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验 ONCOLOGY 肿瘤学 PHARMACOLOGY & PHARMACY 药学 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学
4区 4区 4区 4区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验 ONCOLOGY 肿瘤学 PHARMACOLOGY & PHARMACY 药学 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学
4区 4区 4区 4区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:MEDICINE, RESEARCH & EXPERIMENTAL SCIE Q3 105 / 189

44.7%

学科:ONCOLOGY SCIE Q3 193 / 322

40.2%

学科:PHARMACOLOGY & PHARMACY SCIE Q3 188 / 354

47%

学科:RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING SCIE Q2 78 / 204

62%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:MEDICINE, RESEARCH & EXPERIMENTAL SCIE Q2 74 / 189

61.11%

学科:ONCOLOGY SCIE Q2 128 / 322

60.4%

学科:PHARMACOLOGY & PHARMACY SCIE Q2 136 / 354

61.72%

学科:RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING SCIE Q2 79 / 204

61.52%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:7.8 SJR:0.607 SNIP:0.555
学科类别 分区 排名 百分位
大类:Medicine 小类:Radiology, Nuclear Medicine and Imaging Q1 37 / 333

89%

大类:Medicine 小类:Oncology Q1 83 / 404

79%

大类:Medicine 小类:Pharmacology Q1 75 / 313

76%

大类:Medicine 小类:Cancer Research Q2 74 / 230

68%

期刊发文

  • Long Noncoding RNA Regulator of Reprogramming Regulates Cell Growth, Metastasis, and Cisplatin Resistance in Gastric Cancer via miR-519d-3p/HMGA2 Axis

    Author: Jin, Wenhua; Zhang, Hua; Li, Meng; Lin, Sen

    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 122-131. DOI: 10.1089/cbr.2019.3525

  • LncRNA IUR Is Downregulated in Gastric Carcinoma and Associated with Poor Survival

    Author: Ou, Rui; Liu, Xin

    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 116-121. DOI: 10.1089/cbr.2019.3436

  • Gene Silencing of Transcription Factor TEAD4 Inhibits Esophageal Cancer Cells by Regulating TCF7

    Author: He, Songlin; Gao, Ke; Mao, Long; Bhushan, Sandeep; Xiao, Zongwei

    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 132-139. DOI: 10.1089/cbr.2020.3870

  • Survival Advantages in Gastric Cancer Patients Receiving Preoperative SOX Regimen Chemotherapy

    Author: Zhang, Qian; Zhang, Qinghua; Yan, Hui; You, Yanjie; Cao, Juan; Wang, Wenfan; Zhao, Dan; Zhang, Xiaoxu; Wu, Jing; Chen, Zhiqiang; Yang, Wenjun

    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 81-88. DOI: 10.1089/cbr.2020.3970

  • Effect of Oral Nutritional Supplements on Patients with Esophageal Cancer During Radiotherapy

    Author: Yang, Liping; Gao, Jing; Zhou, Yan; Tao, Zhenchao; He, Jian; Yang, Jing; Wang, Ru; Zhang, Yangyang; Huang, Yifan; Zhou, Lingran; Sun, Bin

    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 89-94. DOI: 10.1089/cbr.2020.3888

  • Circ_0003789 Facilitates Gastric Cancer Progression by Inducing the Epithelial-Mesenchymal Transition through the Wnt/beta-Catenin Signaling Pathway

    Author: Shao, Zhongbao; Yuan, Chang; Hu, Junbao; Wu, Yuli; Zeng, Chong

    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 102-110. DOI: 10.1089/cbr.2020.4044

  • Diagnostic and Prognostic Value of Serum miR-296-5p and miR-28-3p in Human Gastric Cancer

    Author: Guo, Yuntong; Cui, Xiaolong; Zhang, Yu; Ma, Xiaobo; Ren, Aigang; Huang, He

    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 95-101. DOI: 10.1089/cbr.2020.4144

  • Effects of Citrus aurantium L. on Gastrointestinal Motility and Gastric Cancer Cell Proliferation

    Author: Gao, Meng; Yang, Wuliang

    Journal: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2023; Vol. 38, Issue 2, pp. 111-115. DOI: 10.1089/cbr.2020.4267